Electromed (ELMD) Q1 2027 earnings review
Electromed's homecare sales accelerate, but its hospital orders drop
Electromed, the maker of the SmartVest vibrating vest that clears mucus from patients' lungs, grew its core homecare business fast while its smaller hospital and distributor channels shrank. Direct homecare sales rose 18% from a year ago as six recently hired sales representatives ramped up without dragging down output per rep. A 40% drop in non-homecare orders by our math held total revenue growth to 11%, but the shift toward direct patient billing lifted gross margin to 80% and profit per share to $0.32.
| Direct homecare revenue | $17.5M +17.6% from a year ago |
|---|---|
| Total revenue | $18.7M +10.6% from a year ago |
| Gross margin | 80.0% 78.1% a year ago |
| Gross margin outlook | Raised to 80%+ from 78%+ previously |
⚖️ Verdict: 🟢 Bullish
The story got better because the expanded sales force kept yearly revenue per rep at $1.11 million, easing the risk that training new hires would stall homecare growth. Management also raised its long-term gross margin floor to 80% and spent $4 million buying back stock after pausing for two quarters. One caution: uncollected insurance bills topped $30 million, which kept operating cash flow near zero, and chief executive Jim Cunniff is still set to retire in April with no successor named.
The question now is whether the expanded sales force can keep total revenue growing at least 10% while new lung drugs enter the market and hospital orders lag. Either the 63 homecare reps beat the middle of their productivity target as they did in the past two years, or weaker hospital orders and competing drug treatments pull total growth into the single digits. Next quarter's homecare rep count and prescription trends will tell.
🐂 Bull Case
New Sales Reps Expanded Homecare Without Hurting Productivity
Electromed relies on field sales representatives to persuade lung doctors to prescribe its SmartVest airway-clearance vest for home use. The medical-device maker hired six additional reps late last quarter, which raised concern that average output per rep would dip while the newcomers spent four to six months learning their territories.
Direct homecare sales instead accelerated to 17.6% growth from a year ago, reaching $17.5 million. Management said the gain came "primarily due to an increase in sales representatives and increased sales representative productivity". The business averaged 63 homecare reps, up from 57 a year ago, while yearly homecare revenue per rep rose 5.4% to $1,109,000.
That reading sits "within Electromed’s target range for the year of $1,050,000 to $1,150,000". Beating last year's first-quarter productivity while absorbing six June hires shows that broader insurance coverage and clinic demand are filling new territories quickly. However, by our math, 63 reps producing at the $1.10 million middle of the target range would generate only 4% full-year homecare growth, so reps must stay above the midpoint.
What to watch: period-end sales rep headcount and Smart Order electronic-prescribing share on the conference call. Reaching the 67-territory full-year plan while keeping productivity above $1.12 million would sustain double-digit homecare growth.
Direct Patient Sales Lifted Gross Margin to 80%
When Electromed sells a SmartVest directly to a patient and bills their insurer, it keeps the full price rather than sharing a cut with a medical-equipment distributor. Chief executive Jim Cunniff highlighted an 80.0% gross margin, "demonstrating the strength of our direct-to-patient model and operating leverage".
Gross margin climbed 1.9 percentage points from 78.1% a year ago because the cost of making the vests fell by 1.8 percentage points of revenue, to 20.0%. Direct homecare rose to 93.7% of total sales as lower-margin distributor and hospital orders shrank. In its investor presentation, the company raised its benchmark, stating that "Electromed expects 80% gross margins to continue improving going forward".
What to watch: gross margin in the second quarter when hospital orders typically recover. Holding 80% even when lower-margin hospital sales rebound would show that factory efficiencies, not just channel mix, are supporting profitability.
Management Bought Back $4.3 Million of Stock
Electromed approved a $10 million share-buyback plan a year ago, but management spent only $0.15 million in the third quarter and nothing in the fourth quarter while cash piled up. In the first quarter, the company resumed buying and spent $4.3 million on its own shares, using 71% of its remaining $6.1 million allowance by our math.
The purchases cut issued shares by 1.5% from June, to 8.24 million, though diluted weighted-average shares still ticked up 0.9% from a year ago because of employee stock awards. Putting cash back to work reverses the second-half pause and reduces the chance that management is hoarding cash for a large acquisition.
What to watch: whether the board approves a new buyback allowance once the final $1.8 million runs out. A fresh authorization would confirm that returning cash remains ahead of buying other businesses.
🐻 Bear Case
Hospital and Distributor Sales Dropped 40%
Electromed lists hospital and distributor channels in its presentation as a way to expand beyond homecare. One year ago those channels grew fast, with hospital sales up 52% and distributor sales up 41%. This quarter, both went into reverse and dragged total company revenue growth down to 10.6%, its slowest pace in more than a year.
- Total non-homecare revenue: $1.2 million, down 40% from $2.0 million a year ago by our math
- Hospital revenue: $0.7 million, down 31.6% from a year ago
- Homecare distributor revenue: $0.4 million, down 55.9% from a year ago
- Other revenue: $0.1 million, down 23.0% from a year ago
Hospital purchases depend on capital budgets and were hurt by a tough comparison from a year ago. Still, hospital sales also fell 29% in the fourth quarter and missed management's 20% growth goal last year, so the channel is struggling to gain traction despite dedicated hospital sales liaisons.
What to watch: hospital revenue in the third quarter, when it faces another 43% growth comparison from last year. Another drop would leave Electromed entirely reliant on homecare to keep total revenue growth above 10%.
Uncollected Bills Kept Operating Cash Flow Near Zero
Medicare and insurers pay for about 95% of Electromed's homecare vests in monthly installments over roughly 13 months, while the company records revenue earlier. As a result, accounts receivable—money owed by customers and insurers—rose to $30.3 million, up 22.3% from a year ago by our math against 10.6% revenue growth.
Combined with $3.2 million of annual staff bonus payouts, the buildup in uncollected bills held operating cash flow to $0.37 million on $2.76 million of net income. That 13.5% cash conversion rate follows a full year in which operating cash flow fell even as profit jumped 50%. The credit-loss allowance on receivables also rose from $45,000 to $75,000 over the past three months.
What to watch: the aging of receivables over one year old in the quarterly filing. A faster rise in old balances than in Medicare sales would signal slower insurance collection rather than normal installment timing.
Risks This Quarter Didn't Answer
Four standing risks received no new figures in the earnings release and depend on the conference call or the quarterly filing for an update.
- Chief executive transition: Jim Cunniff plans to retire around April 2, 2027, and the release gave no update on the board's search for his replacement.
- Drug competition: Bronchiectasis, a lung condition where airways widen and trap mucus, drove 74% of trailing homecare referrals (down from 76% in fiscal 2026); the release did not address whether new lung drugs like Brinsupri are slowing vest prescriptions.
- Medicare reliance: Medicare accounts for 48% of homecare sales under a single billing code (E0483), leaving the sole product exposed to any government rate change.
- Related-party supplier: The quarterly filing will show whether payments to a parts supplier linked to a former director kept rising after jumping 64% last year.
💲 Other KPIs
Operating profit rose 30.7% from a year ago, lifting operating margin by 2.9 percentage points to 18.7%. Selling, general and administrative expenses—sales pay, travel and office overhead—grew 8.6% to $11.2 million, falling by 1.1 percentage points of revenue as the larger sales team brought in more orders per dollar of overhead.
Cash fell by $4.58 million over the past three months from $20.45 million in June, because Electromed spent $4.33 million buying back stock and paid $3.24 million in annual employee bonuses. The medical-device maker still carries no debt and holds $44.9 million in working capital.
🔮 Guidance
Unchanged. The full-year target calls for $1.10 million at the middle of the range, about 4% below last year's $1,145,000 result. By our math, 63 reps at that midpoint would lift homecare sales only 4% this year. However, Electromed beat its initial productivity target by about 10% on average over the past two years; if the pattern holds, productivity would top $1.20 million.
Raised. In its investor presentation, the company lifted its baseline gross margin target by two percentage points, stating that "Electromed expects 80% gross margins to continue improving going forward". It is the second raise in two years—from the mid-70s in early fiscal 2026 to 78%, and now 80%—as direct homecare sales make up a larger share of the business.
❓ Key Questions
How many sales representatives worked in homecare at quarter-end?
Electromed reported an average of 63 homecare reps in Q1 after ending Q4 with 64 total reps, including hospital liaisons. Knowing the exact period-end homecare count shows whether hiring is on track for the 67-territory full-year target.
Are doctors prescribing SmartVest alongside the new Brinsupri drug?
Bronchiectasis accounted for 74% of trailing homecare referrals, down from 76% in fiscal 2026. Investors need prescription data showing whether new oral lung drugs are bringing more patients into clinics or replacing airway-clearance vests.
What is the timeline for naming a new chief executive?
Chief executive Jim Cunniff plans to retire around April 2, 2027, less than five months away. The commercial expansion and payer-contracting strategy has run under his leadership for three years, and no successor has been named.
Why did accounts receivable grow twice as fast as revenue?
Net receivables rose 22.3% from a year ago to $30.3 million while sales grew 10.6%, and the credit-loss allowance rose from $45,000 to $75,000. Management has not broken out collection days by insurer.